Case Report: Neurological immune-related adverse events with anti-PD-1 based immunotherapy in cervical cancer - Takeaways - MDSpire

Case Report: Neurological immune-related adverse events with anti-PD-1 based immunotherapy in cervical cancer

  • By

  • Gaia Passarella

  • Sofia Vella

  • Erminia Ferrario

  • Nicoletta Provinciali

  • Diego Luigi Cortinovis

  • Stefania Canova

  • May 14, 2026

  • 0 min

Share

  • 1

    Cervical cancer is the fourth most common cancer among women, with significant incidence and mortality rates globally.

  • 2

    Immune checkpoint inhibitors like cemiplimab show promise in treating recurrent and metastatic cervical cancer.

  • 3

    Immune-related adverse events (irAEs) can occur during or after immunotherapy, affecting various organs, including the nervous system.

  • 4

    The case study highlights the delayed onset of neurological irAEs during steroid tapering after cemiplimab treatment.

  • 5

    Structured follow-up is crucial for early identification and management of irAEs in patients receiving immunotherapy.

Original Source(s)

Case Report: Neurological immune-related adverse events with anti-PD-1 based immunotherapy in cervical cancer

  • by Gaia Passarella, Sofia Vella, Erminia Ferrario, Nicoletta Provinciali, Diego Luigi Cortinovis, Stefania Canova

  • May 14, 2026

Related Content

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report